Exact Mass: 528.2207
Exact Mass Matches: 528.2207
Found 500 metabolites which its exact mass value is equals to given mass value 528.2207
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Satratoxin H
D009676 - Noxae > D011042 - Poisons > D014255 - Trichothecenes D009676 - Noxae > D011042 - Poisons > D009183 - Mycotoxins CONFIDENCE isolated standard
16,17-Dihydro-16alpha,17-dihydroxygibberellin A4 17-glucoside
16,17-Dihydro-16alpha,17-dihydroxygibberellin A4 17-glucoside belongs to the class of organic compounds known as diterpene glycosides. These are diterpenoids in which an isoprene unit is glycosylated. 16,17-Dihydro-16alpha,17-dihydroxygibberellin A4 17-glucoside is found in cereals and cereal products. 16,17-Dihydro-16alpha,17-dihydroxygibberellin A4 17-glucoside is a constituent of rice (Oryza sativa) flower anthers. Constituent of rice (Oryza sativa) flower anthers. 16,17-Dihydro-16a,17-dihydroxygibberellin A4 17-glucoside is found in cereals and cereal products.
Dutasteride
Dutasteride belongs to a class of drugs called 5-alpha-reductase inhibitors, which block the action of the 5-alpha-reductase enzymes that convert testosterone into dihydrotestosterone (DHT). Finasteride also belongs to this group, but while dutasteride inhibits both isoforms of 5-alpha reductase, finasteride inhibits only one. Even so, a clinical study done by GlaxoSmithKline, the EPICS trial, did not find dutasteride to be more effective than finasteride in treating BPH. [Wikipedia] G - Genito urinary system and sex hormones > G04 - Urologicals > G04C - Drugs used in benign prostatic hypertrophy > G04CB - Testosterone-5-alpha reductase inhibitors D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D065088 - Steroid Synthesis Inhibitors D004791 - Enzyme Inhibitors > D065088 - Steroid Synthesis Inhibitors > D058891 - 5-alpha Reductase Inhibitors C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C242 - Anti-Androgen COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C2319 - 5 Alpha-Reductase Inhibitor C1892 - Chemopreventive Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
(2-((5-Chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
Methanone, 1,1'-(1,4-piperazinediyl)bis(1-(6-(1H-benzimidazol-2-yl)-2-pyridinyl)-
C308 - Immunotherapeutic Agent
Felotaxel
Ibutamoren
Cinnabarone
Methyl 3beta-acetoxy-6-hydroxy-1-oxomeliac-14-enoate
2alpha-acetoxy-9alpha-benzoyloxy-5alpha,7beta,10beta,15-tetrahydroxy-11(15->1)-abeotaxa-4(20),11-dien-13-one|2??-Acetoxy-9??-benzoyloxy-5??,7??,10??,15-tetrahydroxy-11(15鈥樏傗垎1)-abeotaxa-4(20),11-dien-13-one
bistratamide G
A homodetic cyclic peptide that consists of L-valine as the amino acid residue. It is isolated from Lissoclinum bistratum and exhibits antitumour activity against the human colon tumour cell line.
(?)-2-(Acetyloxy)-8-(furan-3-yl)dodecahydro-3,3,5,7a-tetramethyl-10,13-dioxo-1,5-methano-2H,8H-oxireno[1,8]cycloocta[1,2-f][2]benzopyran-4-acetic acid methyl ester
1,3,6,8-Tetramethyl-4,5-divinyl-9,10-dihydro-1,3-biphenanthrene-2,2,7,7-tetrol
3-Xyloside-(3beta,14beta)-3,14-Dihydroxy-19-oxobufa-5,7,20,22-tetraenolide
Dutasteride
G - Genito urinary system and sex hormones > G04 - Urologicals > G04C - Drugs used in benign prostatic hypertrophy > G04CB - Testosterone-5-alpha reductase inhibitors D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D065088 - Steroid Synthesis Inhibitors D004791 - Enzyme Inhibitors > D065088 - Steroid Synthesis Inhibitors > D058891 - 5-alpha Reductase Inhibitors C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C242 - Anti-Androgen COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C2319 - 5 Alpha-Reductase Inhibitor C1892 - Chemopreventive Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Lurasidone HCl
Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is an antagonist of both dopamine D2 and 5-HT7 with IC50s of 1.68 and 0.495 nM, respectively. Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is also a partial agonist of 5-HT1A receptor with an IC50 of 6.75 nM.
C25H36O12_2,7-Octadienoic acid, 6-hydroxy-2,6-dimethyl-, (1aR,1bS,2S,5aS,6R,6aS)-2-(beta-D-glucopyranosyloxy)-1a,1b,2,5a,6,6a-hexahydro-5a-hydroxy-1a-methyloxireno[4,5]cyclopenta[1,2-c]pyran-6-yl ester, (2E,6S)
[(1aR,1bS,2S,5aS,6R,6aS)-5a-hydroxy-1a-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1b,2,6,6a-tetrahydrooxireno[1,2]cyclopenta[4,5-b]pyran-6-yl] (2E,6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoate
methyl (2R)-2-(acetyloxy)-2-[(1S,3S,7R,8R,9R,12S,13R)-13-(furan-3-yl)-6,6,8,12-tetramethyl-17-methylidene-5,15-dioxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]acetate
[(1aR,1bS,2S,5aS,6R,6aS)-5a-hydroxy-1a-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1b,2,6,6a-tetrahydrooxireno[1,2]cyclopenta[4,5-b]pyran-6-yl] (2E,6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoate_major
[(1aR,1bS,2S,5aS,6R,6aS)-5a-hydroxy-1a-methyl-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1b,2,6,6a-tetrahydrooxireno[1,2]cyclopenta[4,5-b]pyran-6-yl] (2E,6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoate_35.8\\%
Ala Glu Phe Tyr
Ala Glu Tyr Phe
Ala Phe Glu Tyr
Ala Phe Tyr Glu
Ala Tyr Glu Phe
Ala Tyr Phe Glu
Cys Phe Phe Ile
Cys Phe Pro Tyr
Cys Phe Tyr Pro
Cys His Asn Arg
Cys His Arg Asn
Cys Ile Met Tyr
Cys Ile Tyr Met
Cys Leu Met Tyr
Cys Leu Tyr Met
Cys Met Ile Tyr
Cys Met Leu Tyr
Cys Met Tyr Ile
Cys Met Tyr Leu
Cys Asn His Arg
Cys Asn Arg His
Cys Pro Phe Tyr
Cys Pro Tyr Phe
Cys Arg His Asn
Cys Arg Asn His
Cys Tyr Phe Pro
Cys Tyr Ile Met
Cys Tyr Leu Met
Cys Tyr Met Ile
Cys Tyr Met Leu
Cys Tyr Pro Phe
Asp Phe Phe Thr
Asp Phe Thr Phe
Asp Thr Phe Phe
Glu Ala Phe Tyr
Glu Ala Tyr Phe
Glu Phe Ala Tyr
Glu Phe Phe Ser
Glu Phe His Pro
Glu Phe Pro His
Glu Phe Ser Phe
Glu Phe Tyr Ala
Glu His Phe Pro
Glu His Ile Met
Glu His Leu Met
Glu His Met Ile
Glu His Met Leu
Glu His Pro Phe
Glu Ile His Met
Glu Ile Met His
Glu Leu His Met
Glu Leu Met His
Glu Met His Ile
Glu Met His Leu
Glu Met Ile His
Glu Met Leu His
Glu Pro Phe His
Glu Pro His Phe
Glu Ser Phe Phe
Glu Tyr Ala Phe
Glu Tyr Phe Ala
Phe Ala Glu Tyr
Phe Ala Tyr Glu
Phe Cys Pro Tyr
Phe Cys Tyr Pro
Phe Asp Phe Thr
Phe Asp Thr Phe
Phe Glu Ala Tyr
Phe Glu Phe Ser
Phe Glu His Pro
Phe Glu Pro His
Phe Glu Ser Phe
Phe Glu Tyr Ala
Phe Phe Asp Thr
Phe Phe Glu Ser
Phe Phe Ser Glu
Phe Phe Thr Asp
Phe His Glu Pro
Phe His Pro Glu
Phe Met Met Thr
Phe Met Thr Met
Phe Pro Cys Tyr
Phe Pro Glu His
Phe Pro His Glu
Phe Pro Tyr Cys
Phe Ser Glu Phe
Phe Ser Phe Glu
Phe Thr Asp Phe
Phe Thr Phe Asp
Phe Thr Met Met
Phe Tyr Ala Glu
Phe Tyr Cys Pro
Phe Tyr Glu Ala
Phe Tyr Pro Cys
His Cys Asn Arg
His Cys Arg Asn
His Glu Phe Pro
His Glu Ile Met
His Glu Leu Met
His Glu Met Ile
His Glu Met Leu
His Glu Pro Phe
His Phe Glu Pro
His Phe Pro Glu
His Ile Glu Met
His Ile Met Glu
His Leu Glu Met
His Leu Met Glu
His Met Glu Ile
His Met Glu Leu
His Met Ile Glu
His Met Leu Glu
His Met Asn Gln
His Met Gln Asn
His Asn Cys Arg
His Asn Met Gln
His Asn Gln Met
His Asn Arg Cys
His Pro Glu Phe
His Pro Phe Glu
His Gln Met Asn
His Gln Asn Met
His Arg Cys Asn
His Arg Asn Cys
Ile Cys Met Tyr
Ile Cys Tyr Met
Ile Glu His Met
Ile Glu Met His
Ile His Glu Met
Ile His Met Glu
Ile Met Cys Tyr
Ile Met Glu His
Ile Met His Glu
Ile Met Tyr Cys
Ile Tyr Cys Met
Ile Tyr Met Cys
Leu Cys Met Tyr
Leu Cys Tyr Met
Leu Glu His Met
Leu Glu Met His
Leu His Glu Met
Leu His Met Glu
Leu Met Cys Tyr
Leu Met Glu His
Leu Met His Glu
Leu Met Tyr Cys
Leu Tyr Cys Met
Leu Tyr Met Cys
Met Cys Ile Tyr
Met Cys Leu Tyr
Met Cys Tyr Ile
Met Cys Tyr Leu
Met Glu His Ile
Met Glu His Leu
Met Glu Ile His
Met Glu Leu His
Met Phe Met Thr
Met Phe Thr Met
Met His Glu Ile
Met His Glu Leu
Met His Ile Glu
Met His Leu Glu
Met His Asn Gln
Met His Gln Asn
Met Ile Cys Tyr
Met Ile Glu His
Met Ile His Glu
Met Ile Tyr Cys
Met Leu Cys Tyr
Met Leu Glu His
Met Leu His Glu
Met Leu Tyr Cys
Met Met Phe Thr
Met Met Thr Phe
Met Asn His Gln
Met Asn Gln His
Met Gln His Asn
Met Gln Asn His
Met Thr Phe Met
Met Thr Met Phe
Met Tyr Cys Ile
Met Tyr Cys Leu
Met Tyr Ile Cys
Met Tyr Leu Cys
Asn Cys His Arg
Asn Cys Arg His
Asn His Cys Arg
Asn His Met Gln
Asn His Gln Met
Asn His Arg Cys
Asn Met His Gln
Asn Met Gln His
Asn Gln His Met
Asn Gln Met His
Asn Arg Cys His
Asn Arg His Cys
Pro Cys Phe Tyr
Pro Cys Tyr Phe
Pro Glu Phe His
Pro Glu His Phe
Pro Phe Cys Tyr
Pro Phe Glu His
Pro Phe His Glu
Pro Phe Tyr Cys
Pro His Glu Phe
Pro His Phe Glu
Pro Ser Tyr Tyr
Pro Tyr Cys Phe
Pro Tyr Phe Cys
Pro Tyr Ser Tyr
Pro Tyr Tyr Ser
Gln His Met Asn
Gln His Asn Met
Gln Met His Asn
Gln Met Asn His
Gln Asn His Met
Gln Asn Met His
Arg Cys His Asn
Arg Cys Asn His
Arg His Cys Asn
Arg His Asn Cys
Arg Asn Cys His
Arg Asn His Cys
Ser Glu Phe Phe
Ser Phe Glu Phe
Ser Phe Phe Glu
Ser Pro Tyr Tyr
Ser Tyr Pro Tyr
Ser Tyr Tyr Pro
Thr Asp Phe Phe
Thr Phe Asp Phe
Thr Phe Phe Asp
Thr Phe Met Met
Thr Met Phe Met
Thr Met Met Phe
Tyr Ala Glu Phe
Tyr Ala Phe Glu
Tyr Cys Phe Pro
Tyr Cys Ile Met
Tyr Cys Leu Met
Tyr Cys Met Ile
Tyr Cys Met Leu
Tyr Cys Pro Phe
Tyr Glu Ala Phe
Tyr Glu Phe Ala
Tyr Phe Ala Glu
Tyr Phe Cys Pro
Tyr Phe Glu Ala
Tyr Phe Pro Cys
Tyr Ile Cys Met
Tyr Ile Met Cys
Tyr Leu Cys Met
Tyr Leu Met Cys
Tyr Met Cys Ile
Tyr Met Cys Leu
Tyr Met Ile Cys
Tyr Met Leu Cys
Tyr Pro Cys Phe
Tyr Pro Phe Cys
Tyr Pro Ser Tyr
Tyr Pro Tyr Ser
Tyr Ser Pro Tyr
Tyr Ser Tyr Pro
Tyr Tyr Pro Ser
Tyr Tyr Ser Pro
16,17-Dihydro-16a,17-dihydroxygibberellin A4 17-glucoside
Fmoc-O-tert-Butyl-L-serine 3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl ester
METHYL2,4-DIMETHYL-5-(TERT-BUTOXYCARBONYL)-3-PYRROLE PROPIONATE
(+)-4,5-Bis[hydroxy(diphenyl)methyl]-2-methyl-2-phenyl-1,3-dioxolane
dexamethasone acefurate
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid
(3aR,4R,7S,7aS)-rel-2-[[(1R,2R)-2-[[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione hydrochloride (1:1)
Celesticetin A
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D055231 - Lincosamides
Lurasidone Hydrochloride
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is an antagonist of both dopamine D2 and 5-HT7 with IC50s of 1.68 and 0.495 nM, respectively. Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is also a partial agonist of 5-HT1A receptor with an IC50 of 6.75 nM.
[(2S,3S,4S,6R)-6-[[(1S,3R,4R)-3-ethyl-3,4,10,12-tetrahydroxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]-3-hydroxy-2-methyloxan-4-yl]-dimethylazanium
(1S)-N-(4-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-(1-oxo-2-phenylethyl)-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]carboxamide
(6R,11R,13R,14S,15S,21E,23S,27R)-27-hydroxy-23-[(1S)-1-hydroxyethyl]-9,15-dimethylspiro[4,12,17,24-tetraoxapentacyclo[21.3.1.113,16.06,11.06,15]octacosa-1,9,19,21-tetraene-14,2-oxirane]-3,18-dione
methyl (2R)-2-acetyloxy-2-[(1S,3S,7R,8R,9R,12S,13S)-13-(furan-3-yl)-6,6,8,12-tetramethyl-17-methylidene-5,15-dioxo-2,14-dioxatetracyclo[7.7.1.01,12.03,8]heptadecan-7-yl]acetate
(1R,3aS,3bS,5aR,9aR,9bR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (Z)-tridec-9-enoate
[2-Propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropyl] propanoate
[1-Acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] butanoate
[7-(Acetyloxymethyl)-4,5-dihydroxy-3,11,11,14-tetramethyl-15-oxo-6-tetracyclo[7.5.1.01,5.010,12]pentadeca-2,7-dienyl] deca-2,4,6,8-tetraynoate
(1E,6R,11R,13R,14S,15S,19E,21E,23S,27R)-27-hydroxy-23-[(1S)-1-hydroxyethyl]-9,15-dimethylspiro[4,12,17,24-tetraoxapentacyclo[21.3.1.113,16.06,11.06,15]octacosa-1,9,19,21-tetraene-14,2-oxirane]-3,18-dione
D009676 - Noxae > D011042 - Poisons > D014255 - Trichothecenes D009676 - Noxae > D011042 - Poisons > D009183 - Mycotoxins
16,17-Dihydro-16alpha,17-dihydroxygibberellin A4 17-glucoside
CID 10369659
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D055231 - Lincosamides
4,5'-diethenyl-1',3,6',8-tetramethyl-9',10'-dihydro-[1,3'-biphenanthrene]-2,2',7,7'-tetrol
6-hydroxy-2-methyl-10-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3,9-dioxatricyclo[4.4.0.0²,⁴]dec-7-en-5-yl 6-hydroxy-2,6-dimethylocta-2,7-dienoate
(2s)-n-[(1r,2r)-2-methoxy-1-[(2s,3r,4r,5s,6s)-3,4,5-trihydroxy-6-{[2-(2-hydroxybenzoyloxy)ethyl]sulfanyl}oxan-2-yl]propyl]-1-methylpyrrolidine-2-carboximidic acid
3-(acetyloxy)-7-ethenyl-2,8a,9-trihydroxy-1,1,4a,7-tetramethyl-5,8-dioxo-octahydrophenanthren-4-yl benzoate
methyl (2r)-2-(acetyloxy)-2-[(1r,2s,5r,6r,13s,14r,16s)-6-(furan-3-yl)-14-hydroxy-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-10-en-16-yl]acetate
(4ar,6s,7r,7as)-7-methyl-3-oxo-hexahydro-1h-cyclopenta[c]pyran-6-yl (4s,5s,6s)-5-ethenyl-4-(2-hydroxyethyl)-6-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5,6-dihydro-4h-pyran-3-carboxylate
methyl 2-[(1r,2r,5r,6r,13r,14s,16r)-14-(acetyloxy)-6-(furan-3-yl)-13-hydroxy-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-10-en-16-yl]acetate
(1'r,2s,3'r,8'r,12'e,15'r,17's,18's,25's,26's,28'r)-28'-hydroxy-5',13',17',26'-tetramethyl-2',10',16',24',29'-pentaoxaspiro[oxirane-2,27'-pentacyclo[23.2.1.1¹⁵,¹⁸.0³,⁸.0⁸,²⁶]nonacosane]-4',12',19',21'-tetraene-11',23'-dione
methyl 2-[(2s,3r,5r,6r,10s,13s,14r,16s)-3-(acetyloxy)-6-(furan-3-yl)-14-hydroxy-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-16-yl]acetate
(3r,5s,7r,10r,12r,14s,15s,18r,19r,22s,23r)-10,22-dihydroxy-7,18-dimethyl-9-oxo-19-(5-oxo-2h-furan-3-yl)-4,6,11-trioxahexacyclo[12.11.0.0³,¹².0⁵,¹⁰.0¹⁵,²³.0¹⁸,²²]pentacos-1(25)-ene-14-carbaldehyde
(1s,12s,18s,19r,20s)-19-ethenyl-18-{[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-17-oxa-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15-pentaene-12-carboxylic acid
(4s,11s,18s)-4,11,18-triisopropyl-7-methyl-6,13-dioxa-20-thia-3,10,17,22,23,24-hexaazatetracyclo[17.2.1.1⁵,⁸.1¹²,¹⁵]tetracosa-1(21),2,5(24),7,9,12(23),14,16,19(22)-nonaene-2,9,16-triol
methyl (1r,3s,6s,7s,10r,11r)-10-[(1r,6r)-6-[(acetyloxy)methyl]-1,5,5-trimethyl-4-oxocyclohex-2-en-1-yl]-6-(furan-3-yl)-7,11-dimethyl-4-oxo-2,5-dioxatricyclo[5.4.0.0¹,³]undecane-11-carboxylate
{2,6,6,14,19-pentamethyl-3,8,15,20-tetraoxo-7,16,18-trioxapentacyclo[12.6.1.0²,¹².0⁵,¹⁰.0¹⁷,²¹]henicosa-4,10-dien-11-yl}methyl 3-methylbutanoate
methyl (1s,4as,7as)-7-[(1s)-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-yl]-1-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carboxylate
(1s,3r,7r,10s,13r,14s,18r,19r)-1-hydroxy-9,9,18-trimethyl-18-[(2s)-2-methyl-3-[(2z)-4-methyl-5-oxofuran-2-ylidene]propanoyl]-4,8,15-trioxapentacyclo[11.7.0.0³,⁷.0³,¹⁰.0¹⁴,¹⁹]icosane-5,16-dione
methyl 2-[17-(acetyloxy)-9-(furan-3-yl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-15-yl]acetate
18'-(1-hydroxyethyl)-5',14',26'-trimethyl-2',7',11',17',24'-pentaoxaspiro[oxirane-2,27'-pentacyclo[23.2.1.0³,⁹.0⁶,⁸.0⁹,²⁶]octacosane]-4',13',19',21'-tetraene-12',23'-dione
3-{4-[4-ethoxy-6-(2-methoxy-2-oxoethyl)-5,5,7-trimethyl-6,7-dihydro-4h-1-benzofuran-2-yl]-2-(furan-3-yl)-3-methyl-6-oxo-2h-pyran-3-yl}propanoic acid
3-{2-hydroxy-5-[(1r)-3-(2-hydroxy-4-methoxyphenyl)-1-(4-hydroxyphenyl)propyl]-4-methoxyphenyl}-1-(4-hydroxyphenyl)propan-1-one
methyl 2-[(1s,2r,4s,5r,9r,10r,13r,14s,15s,17s)-17-(acetyloxy)-9-(furan-3-yl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-15-yl]acetate
2α-acetoxy-9α-benzoyloxy-5α,7β,10β,15-tetra-hydroxy-11(15→1)-abeotaxa-4(20),11-dien-13-one
{"Ingredient_id": "HBIN005268","Ingredient_name": "2\u03b1-acetoxy-9\u03b1-benzoyloxy-5\u03b1,7\u03b2,10\u03b2,15-tetra-hydroxy-11(15\u21921)-abeotaxa-4(20),11-dien-13-one","Alias": "NA","Ingredient_formula": "C29H36O9","Ingredient_Smile": "CC1=C2C(C(C3(C(CC(C(=C)C3C(C2(CC1=O)C(C)(C)O)OC(=O)C)O)O)C)OC(=O)C4=CC=CC=C4)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "133","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
3-o-deacetylorthosiphol i
{"Ingredient_id": "HBIN009309","Ingredient_name": "3-o-deacetylorthosiphol i","Alias": "NA","Ingredient_formula": "C29H36O9","Ingredient_Smile": "CC(=O)OC1C(C(C2CC(C3(C(C2(C1OC(=O)C4=CC=CC=C4)C)C(=O)CC(C3=O)(C)C=C)O)O)(C)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4759","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}